GLYCOMIMETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.27 USD | -2.17% |
|
-9.52% | -88.56% |
| May. 09 | GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50 | MT |
Presenter SpeechWai Kit Ma (Analysts)Hello, everyone. Welcome to the Jefferies London Virtual ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.27
USD
Average target price
0.75
USD
Spread / Average Target
+177.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -88.56% | 17.4M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.44% | 22.27B | |
| -4.18% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- GLYC Stock
- News GlycoMimetics, Inc.
- Transcript : GlycoMimetics, Inc. Presents at Jefferies 2020 Virtual London Healthcare Conference, Nov-19-2020 06